الفهرس | Only 14 pages are availabe for public view |
Abstract HCC is the most prevalent primary liver cancer in adults and the world’s third largest cause of cancer mortality. The incidence of HCC associated with hepatic steatosis disease, like NAFLD, has been rising in recent years all over the world. MR imaging hasn’t been used extensively to assess the diagnostic features of HCC in the context of hepatic steatosis. Previous research has linked a lack of washout or capsule of HCC on MRI to a higher steatosis grade in individuals with NAFLD. Our study included 60 patients who had had a liver MR scan and exhibited MRI features in keeping with HCC. We categorize the patients into two groups: hepatic steatosis and non- hepatic steatosis groups based on MRI hepatic fat signal fraction. LI-RADS major and ancillary features were evaluated in all HCCs. We concluded that hepatic steatosis had a significant association with absent enhancing capsule, late arterial enhancement, as well as a lesion size <50 mm. We also concluded that “fat sparing in solid mass” and ”nonenhancing capsule” ancillary features had a significant association with hepatic steatosis, while “mild-moderate T2 hyperintensity” and “fat in mass, more than adjacent liver” ancillary features had a significant association with absent hepatic steatosis. In conclusion, the findings of our retrospective study is coincide with a recent retrospective studies demonstrated that “enhancing capsule” feature of HCC was less frequently observed in patients with hepatic steatosis compared to non-hepatic steatosis patients. We compared the MRI features of HCC in patients with hepatic steatosis to those in patients without hepatic steatosis. Our findings imply that existing imaging criteria for the noninvasive characterization of HCC in individuals with hepatic steatosis should be utilised with care. RECOMMENDATIONS More study is needed to determine the real utility of MRI as a screening tool in hepatic steatosis patients, according to our findings. More study is also necessary to see if the LI-RADS characteristics can be used to diagnose HCC in patients with hepatic steatosis. |